andrographolide sulfonate
ApprovedSmall molecule
andrographolide sulfonate is one of 52 small molecule programs targeting Acute bronchitis. It is currently in Approved.
3
Indications
3
Total Trials
0
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Chronic Bronchitis
#DrugCompanyPhaseTrials
1Ketek
SanofiApproved
Daliresp
AstraZenecaApproved
Kalydeco
Vertex PharmaceuticalsApproved
Cipro
BayerApproved
Levaquin
WWim Janssens
Approved
Theo-Dur
PfizerApproved
Avelox
BayerPhase 3
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Amoxicillin-Clavulanic Acid
TevaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute bronchitis1 trial
Chronic Bronchitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for andrographolide sulfonate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details